Last reviewed · How we verify
CT327 0.05%
CT327 0.05% is a 11β-HSD1 inhibitor Small molecule drug developed by Creabilis SA. It is currently in Phase 2 development for Moderate to severe psoriasis.
CT327 is a selective inhibitor of 11β-HSD1.
CT327 is a selective inhibitor of 11β-HSD1. Used for Moderate to severe psoriasis.
At a glance
| Generic name | CT327 0.05% |
|---|---|
| Sponsor | Creabilis SA |
| Drug class | 11β-HSD1 inhibitor |
| Target | 11β-HSD1 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 2 |
Mechanism of action
CT327 works by inhibiting the enzyme 11β-HSD1, which is involved in the production of cortisol in the body. This can lead to a reduction in cortisol levels, which may have anti-inflammatory effects.
Approved indications
- Moderate to severe psoriasis
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
- A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (PHASE2)
- Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT327 0.05% CI brief — competitive landscape report
- CT327 0.05% updates RSS · CI watch RSS
- Creabilis SA portfolio CI
Frequently asked questions about CT327 0.05%
What is CT327 0.05%?
How does CT327 0.05% work?
What is CT327 0.05% used for?
Who makes CT327 0.05%?
What drug class is CT327 0.05% in?
What development phase is CT327 0.05% in?
What are the side effects of CT327 0.05%?
What does CT327 0.05% target?
Related
- Drug class: All 11β-HSD1 inhibitor drugs
- Target: All drugs targeting 11β-HSD1
- Manufacturer: Creabilis SA — full pipeline
- Therapeutic area: All drugs in Rheumatology
- Indication: Drugs for Moderate to severe psoriasis
- Compare: CT327 0.05% vs similar drugs
- Pricing: CT327 0.05% cost, discount & access